Northern Trust
ABUS icon

Northern Trust’s Arbutus Biopharma ABUS Stock Holding History

Northern Trust’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.75M Buy
1,277,859
+41,170
+3% +$180K ﹤0.01% 2384
2025
Q4 		$5.95M Sell
1,236,689
-52,724
-4% -$237K ﹤0.01% 2371
2025
Q3 		$5.85M Buy
1,289,413
+5,194
+0.4% +$19.1K ﹤0.01% 2409
2025
Q2 		$3.97M Buy
1,284,219
+618
+0% +$2.05K ﹤0.01% 2595
2025
Q1 		$4.48M Sell
1,283,601
-47,082
-4% -$157K ﹤0.01% 2480
2024
Q4 		$4.35M Buy
1,330,683
+102,241
+8% +$376K ﹤0.01% 2584
2024
Q3 		$4.73M Buy
1,228,442
+177,117
+17% +$679K ﹤0.01% 2508
2024
Q2 		$3.25M Sell
1,051,325
-5,279
-0.5% -$15.8K ﹤0.01% 2640
2024
Q1 		$2.73M Sell
1,056,604
-11,617
-1% -$30.1K ﹤0.01% 2805
2023
Q4 		$2.67M Buy
1,068,221
+2,849
+0.3% +$5.58K ﹤0.01% 2835
2023
Q3 		$2.16M Buy
1,065,372
+21,911
+2% +$45.9K ﹤0.01% 2896
2023
Q2 		$2.4M Buy
1,043,461
+93,571
+10% +$244K ﹤0.01% 2912
2023
Q1 		$2.88M Buy
949,890
+31,149
+3% +$87.9K ﹤0.01% 2775
2022
Q4 		$2.14M Buy
918,741
+18,194
+2% +$43.5K ﹤0.01% 2962
2022
Q3 		$1.72M Buy
900,547
+3,575
+0.4% +$8.42K ﹤0.01% 3099
2022
Q2 		$2.43M Buy
896,972
+122,733
+16% +$314K ﹤0.01% 2950
2022
Q1 		$2.31M Buy
774,239
+39,771
+5% +$122K ﹤0.01% 3028
2021
Q4 		$2.86M Buy
734,468
+33,964
+5% +$132K ﹤0.01% 3034
2021
Q3 		$3M Sell
700,504
-18,655
-3% -$62.2K ﹤0.01% 3052
2021
Q2 		$2.18M Buy
719,159
+586,456
+442% +$1.82M ﹤0.01% 3312
2021
Q1 		$442K Buy
132,703
+18,500
+16% +$71.4K ﹤0.01% 3854
2020
Q4 		$405K Sell
114,203
-5,480
-5% -$19.2K ﹤0.01% 3780
2020
Q3 		$375K Buy
119,683
+16,896
+16% +$51.4K ﹤0.01% 3672
2020
Q2 		$188K Buy
+102,787
New +$168K ﹤0.01% 3776
2019
Q3 		– Sell
-293,078
Closed -$610K – 4250
2019
Q2 		$610K Sell
293,078
-20,682
-7% -$52.9K ﹤0.01% 3507
2019
Q1 		$1.12M Buy
313,760
+2,642
+0.8% +$10.1K ﹤0.01% 3319
2018
Q4 		$1.19M Sell
311,118
-20,590
-6% -$101K ﹤0.01% 3308
2018
Q3 		$3.13M Buy
331,708
+35,292
+12% +$350K ﹤0.01% 2962
2018
Q2 		$2.16M Buy
+296,416
New +$1.76M ﹤0.01% 3171

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Northern Trust's ABUS Position: Q1 2026 in Review

Northern Trust increased its Arbutus Biopharma (ABUS) stake by 3.3% in Q1 2026, buying an estimated $180K and bringing the position to 1,277,859 shares worth $5.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2384.

Northern Trust first reported a position in ABUS in Q2 2018 and has held it in 29 quarters since. The position peaked at $5.95M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Northern Trust held 1,277,859 shares of Arbutus Biopharma worth $5.75M as of Q1 2026.
  • Northern Trust bought 41,170 Arbutus Biopharma shares in Q1 2026, an estimated $180K.
  • Arbutus Biopharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2384 holding.
  • Northern Trust first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 29 quarters since.
  • Northern Trust's Arbutus Biopharma position peaked at $5.95M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.